Use of Small Molecule Inhibitors as Anti-Thrombotic Agents

Project ID: D2016-03

Background

Various ailments, including systemic lupus erythematosus (SLE), rheumatoid arthritis and certain cancers can cause a person to suffer a thrombotic event. There are various therapies currently used for treating pro-thrombotic platelets, including molecules that can be divided into families based on mechanism of action. Anticoagulants are emerging as a favored mode of treatment. However, in some patients these drugs result in severe bleeding tendencies due their ability to inhibit essential pathways for maintaining vascular hemostasis. Furthermore, some patients do no respond to these drugs. It is, therefore, essential to develop new and improved therapy for pro-thrombotic conditions.  

Description

Researchers at The University of Toledo have developed a new family of small molecule inhibitors that may be used to decrease the risk of thrombosis in patients with several diseases.   

Applications

• The small molecule inhibitors developed may be used in the treatment of patients with pro-thrombotic conditions such as lupus, rheumatoid arthritis and cancer

Advantages

• The molecules maintain the ability of platelets to thrombotic agents such as thrombin, collagen and fibrinogen while inhibiting the ability of platelets to become hypersensitive to those thrombotic agents
• The molecules developed here will allow patients susceptible to thrombosis to be treated while maintaining normal hemostasis 

------------------------------------------------------------------------------------------------

US Patent 10,195,177 and 10,702,497